National Institutes of Health, NIAID, Rocky Mountain Laboratories, 903 South 4th Street, Hamilton, MT 59840

68 -- CLEAVABLE PEPTIDE LIBRARY SOL RFQ006 DUE 060500 POC Leona Padrotti, Purchasing Agent (406)363-9395, Lynda Kieres, Contracting Officer E-MAIL: Click here to contact the Purchasing Agent via e-mail, LPadrotti@niaid.nih.gov. 17. The National Institutes of Allergy and Infectious Diseases has a requirement to procure: a peptide library consisting of 2,054 19-mers. This is intended to be procured on a sole source basis. Mimotopes is the only distributor of Cleavable Peptide Libraries consisting of the following features: (1) The individual peptides must be synthesized using multiple parallel synthesis on pins in 96-sample blocks using multipin solid phase peptide synthesis technology to minimize costs and turn around time. (2) The resultant peptides must be biotinylated at the aminoterminus and must be synthesized with a 4-residue (S-G-S-G) spacer arm. The synthesis technology must allow the peptides to be cleaved after synthesis on pins, synthesized in 1-5 mmol quantities, and supplied in the final form as lyophilized powder. In addition, Mass Spectral Analysis must be performed on selected peptides as part of the quality control process. (3) Mimotopes is able to synthesize at least 1,000 peptides per week making it possibleto supply the peptide libraries within 4-5 weeks of the placement of the order. 4) Cleavable peptide libraries can be used to detect antibody/peptide interactions with the goal of mapping all of the epitopes (regions of a protein recognized by antibody) in a particular protein. They are an ideal way of searching through protein antigen sequences for the location of B-cell or helper or cytotoxic T-cell epitopes. Focusing on the studying of genes contributing to the virulence of Group A Streptococcus (GAS). The cleavable peptide libraries will identify the regions of presumptive virulence proteins that are recognized by human antibody. The results will lead to insights about the functional sites within these proteins, their roles during GAS infection, and may ultimately lead to successful vaccine strategies. Closing date for the submission of written responses is forty-five (45) days after the date of this notice. See numbered note 22!! Posted 04/18/00 (W-SN446182). (0109)

Loren Data Corp. http://www.ld.com (SYN# 0261 20000420\68-0002.SOL)